David Brayden
Full Professor - Advanced Drug Delivery University College Dublin
David Brayden is Full Professor of Advanced Drug Delivery at the UCD School of Veterinary Medicine and a Principal Investigator at the Conway Institute at UCD. He is also Adjunct Professor at NUI Galway. Following a Ph.D. in Pharmacology at the University of Cambridge, UK, and a post-doctoral research fellowship at Stanford University, he set up Elan Corporation’s pharmacology laboratory in Dublin in 1991. At Elan, he became a senior scientist. In 2001, he joined UCD as lecturer in veterinary pharmacology and was promoted to Full Professor in 2014. Professor Brayden is a co- lead PI on an SFI Strategic Research Centre (CURAM)) that was awarded 30 million euro by SFI in 2014 and was the Deputy Coordinator of an FP7 grant on oral nanomedicines (2012-2017)). His research team was awarded the Best Research Paper Prize of the Journal of Veterinary Pharmacology and Therapeutics (2005). At UCD, he was Chairman of the Animal Research Ethics Committee (2005-2007) and serves on the main UCD Research Ethics Committee as well as on the President’s Research Strategy Board. On the teaching side, he coordinates undergraduate modules on Biological Fluids and Drug Development and contributes to modules on Cell Communication and to Thematic 4th Level programmes on drug delivery and also leads Drug Discovery and Development modules for Pharmacology students. He works as an independent consultant for drug delivery companies. David was the first Irish academic to be made both a CRS Fellow in 2012 and a Fellow of the American Association of Pharmaceutical Scientists in 2017. In 2024, he was elected as Member of the Royal Irish Academy.
Seminars
How close are we to making oral peptide therapeutics the new standard of care?
As demand grows for more convenient, patient-friendly therapies, how can developers overcome the persistent challenges of poor bioavailability, gastrointestinal degradation and limited permeability without compromising safety or scalability? Is it time to move beyond traditional permeation enhancers towards intrinsically orally available peptides? And which formulation strategies are best positioned to deliver clinically meaningful improvements while supporting successful translation to the clinic?
In this workshop:
- Discover how to increase peptide bioavailability from single digits to 20-30% by modifying physical properties rather than relying on traditional permeation enhancers
- Learn formulation strategies that enable scalable, cost-efficient oral delivery with favourable regulatory safety profiles
- Understand how double-digit bioavailability can be achieved with oral formulations entirely based on FDA approved excipients and peptide design
- Gain insights into selecting the right formulation technology early in preclinical development to avoid costly late-stage failures
- Master the critical transition from injectable to oral modalities to capture multi billiondollar market opportunities.
- Explore the opportunities and challenges of oromucosal administration as an alternative delivery route for peptide therapeutics, overcoming barriers associated with conventional oral and injectable formulations.
- Discover formulation and delivery strategies that enhance peptide absorption across buccal and sublingual while improving bioavailability, patient convenience, and therapeutic performance.
- Presentation of in vivo PK data in pigs from the EU BUCCAL-PEP consortium (2023- 2026).
